Healthcare News

RIYADH, Saudi Arabia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) has expanded capacity for complex care by redesigning the emergency patient...

SANDWICH, United Kingdom, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a clinical-stage biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis...

Corline Biomedical AB (publ) kommer att ställa ut på medicinteknikmässan MEDevice Silicon Valley i Santa Clara, Kalifornien, den 18–19 november 2026. Deltagandet syftar till att etablera kontakter med...

Nxera Pharma Submits Marketing Authorization Application for Vamorolone in South Korea for the Treatment of Duchenne Muscular Dystrophy.

PRESSRELEASE 2026-10-22 Linda Linnér utses som ny CFO för Arcoma AB i Q4 Arcoma AB har utsett Linda Linnér till ny Chief Financial Officer (CFO). Linda tillträder tjänsten under Q4. Linda har...

PRESSRELEASE 2026-10-22 Kvartalsrapport Q3 2026. Stark lönsamhet och positiv utveckling i Nordamerika (MAR) FINANSIELLT SAMMANDRAG Tredje kvartalet Nettoomsättningen för kvartalet uppgick till 26...

Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective,...

Privosegtor dró úr aukningu á léttkeðju taugaþráða (e. neurofilament light chain, NfL) og trefjasúru stoðfrumupróteini (e. glial fibrillary acidic protein, GFAP) í blóðvökva eftir upphaf einkenna...

Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective,...

London, UK, 22 October 2026 - Persica Pharmaceuticals Limited (“Persica”), a clinical-stage biotechnology company developing PP353, a targeted, non-opioid treatment for vertebrogenic Lumbar Back Pain...